PeproStat Haemostat Study in Subjects Undergoing Liver Surgery
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this First in Man study is to evaluate the safety and tolerability, as well as
to explore efficacy of PeproStat, a new peptide based coagulant (haemostat), when used in
patients undergoing open liver resection surgery.